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Abstract
Introduction The present study was conducted to examine the
effect of conjugated docosahexaenoic acid (CDHA) on cell
growth, cell cycle progression, mode of cell death, and
expression of cell cycle regulatory and/or apoptosis-related
proteins in KPL-1 human breast cancer cell line. This effect of
CDHA was compared with that of docosahexaenoic acid (DHA).
Methods KPL-1 cell growth was assessed by colorimetric 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay; cell cycle progression and mode of cell death were
examined by flow cytometry; and levels of expression of p53,
p21Cip1/Waf1, cyclin D1, Bax, and Bcl-2 proteins were examined
by Western blotting analysis. In vivo tumor growth was
examined by injecting KPL-1 cells subcutaneously into the area
of the right thoracic mammary fat pad of female athymic mice fed
a CDHA diet.
Results CDHA inhibited KPL-1 cells more effectively than did
DHA (50% inhibitory concentration for 72 hours: 97 µmol/l and
270 µmol/l, respectively). With both CDHA and DHA growth
inhibition was due to apoptosis, as indicated by the appearance
of a sub-G1 fraction. The apoptosis cascade involved
downregulation of Bcl-2 protein; Bax expression was
unchanged. Cell cycle progression was due to G0/G1 arrest,
which involved increased expression of p53 and p21Cip1/Waf1,
and decreased expression of cyclin D1. CDHA modulated cell
cycle regulatory proteins and apoptosis-related proteins in a
manner similar to that of parent DHA. In the athymic mouse
system 1.0% dietary CDHA, but not 0.2%, significantly
suppressed growth of KPL-1 tumor cells; CDHA tended to
decrease regional lymph node metastasis in a dose dependent
manner.
Conclusion CDHA inhibited growth of KPL-1 human breast
cancer cells in vitro more effectively than did DHA. The
mechanisms of action involved modulation of apoptosis
cascade and cell cycle progression. Dietary CDHA at 1.0%
suppressed KPL-1 cell growth in the athymic mouse system.
Keywords: apoptosis, breast cancer, conjugated docosahexaenoic acid, docosahexaenoic acid, human
Introduction
The etiology of human breast cancer is complex and
remains poorly understood. At least one-third of all human
cancers may be associated with dietary factors [1]. In par-
ticular, it has been hypothesized that dietary fat intake plays
a role in the development and progression of breast cancer.
Evidence from very large prospective studies strongly sug-
gests that there is no association between overall dietary
fat intake and breast cancer in humans [2]. However, such
findings do not necessarily mean that fat has no effect on
breast cancer, because other findings indicate that the type
of dietary fat consumed is of particular importance in breast
CDHA = conjugated docosahexaenoic acid; CLA = conjugated linoleic acid; DHA = docosahexaenoic acid; DMEM = Dulbecco's modifed Eagle's 
minimum essential medium; FBS = fetal bovine serum; IC50 = 50% inhibitory concentration; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide; PBS = phosphate-buffered saline; PUFA = polyunsaturated fatty acid.
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carcinogenesis [3]. Epidemiologic data in Alaskan and
Greenland Eskimos [4,5] and in non-Eskimo populations
[6] indicate that consumption of fish oil correlates with
reduced incidence of breast cancer. In experimental stud-
ies using human breast cancer cells [7,8] eicosapentae-
noic acid and docosahexaenoic acid (DHA) – n-3
polyunsaturated fatty acids (PUFAs) that are abundant in
fish oil – have exhibited protective effects. Perilla oil, which
contains a high level of α-linolenic acid (an n-3 PUFA), sim-
ilarly inhibits mammary carcinogenesis in rats [9,10]. Thus,
n-3 PUFAs appear to be of particular importance in sup-
pression of breast carcinogenesis.
Conjugated fatty acids are positional and geometrical iso-
mers with conjugated double bonds. Conjugated linoleic
acid (CLA) is found in meat from ruminants and in dairy
products [11], and has been shown to have anticarcino-
genic effects [12-14]. It has been reported that CLA
reduces mammary cancer risk in rats [15-17] and inhibits
growth of human breast cancer cells in culture [18]. Lino-
leic acid, an n-6 PUFA, accelerates growth of human breast
cancer cells [8]. Thus, the finding that CLA has the oppo-
site effect is of particular interest. Given that n-3 PUFAs
have been shown to have anticarcinogenic activity in vitro
and in vivo, some conjugated fatty acids converted from n-
3 PUFAs may have greater tumor suppressing activity than
CLA or n-3 PUFAs themselves. We recently showed that
DHA, an n-3 PUFA, suppresses mammary cancer in rats
more effectively than does eicosapentaenoic acid [19].
Conjugated eicosapentaenoic acid is naturally found in
seaweeds [20]. Conjugated DHA (CDHA) is not found nat-
urally and is artificially prepared by alkaline isomerization of
DHA [21]. In the present study, the tumor-suppressing
effect of CDHA was examined in vitro and in vivo, and its
anticarcinogenic activity was compared with that of DHA.
Also, the mechanisms by which CDHA suppresses cancer
cell growth were investigated.
Methods
Human breast cancer cell line and culture conditions
KPL-1 is a human breast carcinoma cell line that was estab-
lished from the malignant effusion of a breast cancer
patient [22]. This cell line is estrogen receptor positive,
grows rapidly in female athymic mice, and often causes
regional lymph node metastasis when inoculated into the
mammary fat pad. KPL-1 cells were maintained in Dul-
becco's modified Eagle's minimum essential medium
(DMEM 0/5921; Sigma, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco BRL,
Grand Island, NY, USA), and were grown at 37°C in 5%
carbon dioxide/95% humidified air.
DHA and preparation of CDHA by alkaline treatment
DHA ethyl ester (purity 97%) was obtained from Bizen
Chemical (Okayama, Japan). CDHA was prepared by alka-
line treatment [21]. Briefly, a solution of potassium hydrox-
ide in ethylene glycol was prepared at a concentration of
21% (weight:weight), and this solution was bubbled with
nitrogen gas. Then, 100 g DHA ethyl ester was added to
1000 ml of the 21% potassium hydroxide/ethylene glycol
solution. The mixture was bubbled with nitrogen gas and
allowed to stand for 10 min at 180°C. The reaction mixture
was cooled and 1000 ml methanol was added. The mixture
was acidified with 2000 ml of 6 N HCl. After dilution with
2000 ml distilled water, the conjugated fatty acid was
extracted with 5000 ml n-hexane. The hexane extract was
then washed with 3000 ml of 30% methanol/distilled
water, washed with 3000 ml distilled water, and finally
evaporated under the nitrogen gas stream to produce
CDHA. DHA isomerized with 21% potassium hydroxide for
10 min preferentially forms conjugated pentaene and con-
jugated hexaene [21]. The purity of CDHA used in the fol-
lowing experiments was approximately 65% (35% was
unreacted and remained as DHA). DHA and CDHA were
stored at -80°C in the dark.
MTT assay
Viable cells exposed to DHA or CDHA were quantified
using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay.
Stock solutions of DHA or CDHA in ethanol were prepared
at a concentration of 500 mmol/l. For each experiment test
compound was prepared from the stock solution and
diluted to a final concentration of 1 µmol/l to 5 × 102 µmol/
l with culture medium. Initially, 5 × 103 KPL-1 cells were
seeded in 96-well culture plates and cultured for 24 hours
to allow them to adhere to the plates. After preincubation,
the culture medium was changed to the experimental
medium supplemented with DHA or CDHA. We used four
concentrations of each test compound, covering a 3-log
range (1 µmol/l to 5 × 102 µmol/l) that was chosen to span
the 50% inhibitory concentration (IC50) determined in pre-
liminary assays. The final concentration of ethanol never
exceeded 0.2% (vol:vol). Control cells were exposed to
test medium supplemented with 0.2% ethanol. After incu-
bation with the test compound for 24, 48 or 72 hours, MTT
(Sigma) was added and the plate samples were then read
in eight wells at an optical density value of 540 nm.
Untreated controls were incubated with culture medium
alone. The percentages of surviving cells, as compared
with untreated controls, were calculated.
Flow cytometry
To evaluate the mode of cell death, asynchronous KPL-1
cells were exposed to DHA or CDHA at IC50 for 72 hours,
in DMEM supplemented with 10% FBS. To evaluate cell
cycle progression, after serum starvation (incubated with
FBS-free medium) for 24 hours synchronous KPL-1 cells
were exposed to each test compound at the same
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concentration in DMEM supplemented with 10% FBS for
0, 3, 6, or 24 hours. Both asynchronous and synchronous
KPL-1 cells were treated as follows. The adhered and float-
ing cells were mixed and washed twice in phosphate-buff-
ered saline (PBS)(-) followed by centrifugation, and fixed in
70% ethanol. Then, the cells were treated with 1 mg/ml
RNase, diluted with PBS(-), and stained with 50 µg/ml pro-
pidium iodide in PBS(-). Cells were analyzed by FACScan
(Becton Dickson, Mountain View, CA, USA) using Cell
Quest software. Cell cycle distribution was quantified with
Modfit LT software (Verity Software House, Topsham, ME,
USA), using a doublet discrimination module to eliminate
the possibility of confusing multiples of G1 cells with ordi-
nary G2 cells.
Western blotting analysis
KPL-1 cells were examined for expression of p53, p21Cip1/
Waf1, cyclin D1, Bax, and Bcl-2 proteins. KPL-1 cells were
exposed to DHA or CDHA for 3, 6 and 24 hours, or for 24,
48 and 72 hours (at the IC50 dose for 72 hours) and com-
pared with unexposed cells. Immunoblotting was per-
formed as previously described [23]. Briefly, cell pellets
were homogenized using lysis buffer (50 mmol/l Tris-HCl
[pH 6.8], 2% SDS, 5 mmol/l β-mercaptoethanol, 10% glyc-
erol). Cell lysates were clarified by centrifugation at 13,500
g for 40 min. Protein concentrations were measured by
Bio-Rad assay (Bio-Rad, Richmond, CA, USA), and 70 µg
protein from each sample was mixed with loading buffer,
electrophoresed on 15% SDS polyacrylamide gels, and
blotted onto nitrocellulose membrane (Hybond-P; Amer-
sham Pharmacia Biotech, Buckinghamshire, UK). The
membranes were blocked with 5% dry milk in Tris-buffered
saline–Tween for 1 hour at room temperature and probed
with anti-p53 (clone DO-7; Dako, Glostrup, Denmark), anti-
p21Cip1/Waf1 (clone SX-118; BD Biosciences, San Jose,
CA, USA), and anti-cyclin D1 (clone P2D11F11; Novocas-
tra Laboratories, Newcastle upon Tyne, UK) antibodies,
and with anti-Bax (BD Biosciences) or anti-Bcl-2 (BD Bio-
sciences) antiserum. Next, the membrane was treated with
peroxidase-conjugated goat antimouse or antirabbit IgG
antiserum (Envision + system HRP; Dako). Immobilized
antigen was detected using ECL plus Western-blotting
detection reagents and hyperfilm (Amersham), according
to the manufacturer's instructions. Intensity of bands was
quantified with the NIH Image1.47 Processing and Analy-
sis program for use with Macintosh computers http://
rsb.info.nih.gov/nih-image/.
Effect of CDHA on KPL-1 tumor growth in female athymic 
mice
Female athymic BALB/c-nu/nu mice (age 4 weeks) were
purchased from Charles River Japan (Atsugi, Japan). After
arrival the mice were randomly assigned to three different
dietary groups, with 10 mice in each group and two cages
for each group. For basal diet without CDHA, an American
Institute of Nutrition (AIN-76 A) standard reference diet
[24] was used. This diet consists of 20% casein, 0.3% DL-
methionine, 55% cornstarch, 10% sucrose, 5% cellulose,
5% corn oil, 3.5% AIN-76 mineral mix, 1.0% AIN-76 vitamin
mix, and 0.2% choline bitartrate. For diets containing 0.2%
or 1.0% CDHA, the appropriate amount of CDHA was
added to the basal diet. The diets were prepared at Orien-
tal Yeast (Chiba, Japan) and were stored in sealed plastic
bags in the dark at 4°C. During the experimental period the
animals were housed in plastic cages with sterilized white
pine chips for bedding. The animal room was maintained
under specific pathogen-free conditions and was control-
led for temperature (22 ± 2°C), light (12-hour cycle), and
humidity (60 ± 10%). After the animals had become accli-
matization to their respective powdered diets over 2 weeks,
the semiconfluent KPL-1 cells growing in DMEM supple-
mented with 10% FBS at 37°C were trypsinized, and 2 ×
107 viable cells/0.25 ml of medium were injected subcuta-
neously into the area of the right thoracic mammary fat pad
using a 26-gauge needle.
The local growing tumor was checked every day before it
became visible, and was measured once a week after it
became visible. Tumor volume was measured with calipers
and calculated using a standard formula [25]: width2 ×
length × 0.5. All mice were killed when the tumors of the
basal diet fed group began to exhibit central necrosis (41
days after tumor cell inoculation), and all animals under-
went necropsy. At necropsy tumors were weighed and all
organs were checked macroscopically. Abnormal organs,
locally growing tumors, and axillary lymph nodes were fixed
in 10% neutral buffered formalin and processed for hema-
toxylin–eosin staining. Axillary lymph nodes were evaluated
microscopically for metastases.
Data analysis
All results are expressed as means ± standard error. In all
in vitro experiments, significance of differences was deter-
mined using the two-tailed Mann–Whitney U-test for
unpaired samples after assuring homogeneity of variance.
In in vivo experiments, after assurance of homogeneity of
variance, analysis was performed using the non-repeated-
measures analysis of variance parametric test or the
Kruskal–Wallis nonparametic test. If the P value of these
pretests was below 0.05, then post hoc analysis was per-
formed using Fisher's protected least significant difference
test to compare body weight, tumor volume, tumor weight,
and frequency of metastasis. P < 0.05 was considered sta-
tistically significant.
Results
Effects of DHA and CDHA in vitro
The number of viable KPL-1 cells decreased after treatment
with DHA and CDHA (Fig. 1). Dose and time dependent
cytotoxity (reduction in cell number to below the initial
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plating density) was observed. For 72 hours of treatment,
the IC50s of DHA and CDHA were 270 and 97 µmol/l,
respectively. CDHA was more cytotoxic than DHA toward
KPL-1 cells.
Mode of cell death
To determine whether the growth inhibitory activity of DHA
and CDHA was related to induction of apoptosis, the effect
of both reagents on the cell cycle was analyzed by flow
Figure 1
Growth inhibition curves of KPL-1 cells after treatment with docosahexaenoic acid (DHA) or conjugated DHA (CDHA) for 24, 48, and 72 hours. 
Shown are means ± standard error for three experiments. The 50% inhibitory concentration (IC50) values indicated are for the 72-hour treatment.
Figure 2
Cell cycle analysis of KPL-1 cells grown in medium alone or treated with 270 µmol/l docosahexaenoic acid (DHA) or 97 µmol/l conjugated DHA (CDHA) 50% inhibitory concentration [IC50] for 72 hours, respectively) for 72 hours
(CDHA) 50% inhibitory concentration [IC50] for 72 hours, respectively) for 72 hours. Appearance of sub-G1 fraction is seen after DHA and CDHA 
treatment.
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cytometry. Representative DNA histograms of asynchro-
nous KPL-1 cells are shown in Fig. 2. At the IC50 for 72
hours, both DHA and CDHA induced appearance of a sub-
G1 fraction, which is characteristic of apoptosis.
Cell cycle progression
Cells in asynchronous cell populations are in different
stages of the cell cycle at any given time, making it difficult
to interpret changes in cell cycle progression precisely. To
examine inhibition of cell growth by DHA or CDHA, syn-
chronous KPL-1 cells were treated with 270 µmol/l DHA or
97 µmol/l CDHA (IC50 concentration for 72 hours). Cell
cycle was synchronized by serum starvation for 24 hours
followed by refeeding. Cell cycle fraction was recorded
after 3, 6, and 24 hours of treatment with each test com-
pound, and was compared with cells incubated in medium
alone. Representative DNA histograms for synchronous
cells and data from three independent experiments are
shown in Fig. 3. Among synchronous cells incubated in
medium alone, 71 ± 2% of cells were in G0/G1 phase and
19 ± 2% were in S phase. At 3 hours after refeeding, the
percentage of cells in G0/G1 decreased to 37 ± 1% and
the percentage in S phase increased to 43 ± 5%. At 6
hours the percentage of cells in G2/M phase increased to
22 ± 0%. In cells treated with DHA or CDHA, cell cycle
progression was comparable with that in cells in medium
alone until 6 hours after re-feeding. However, after 24
hours of incubation with DHA or CDHA, the percentage of
cells in S phase was lower (15 ± 7% and 12 ± 0%, respec-
tively) and the percentage of cells in G0/G1 was higher (53
± 10% and 76 ± 4%, respectively), as compared with cells
incubated in medium alone, suggesting G0/G1 arrest. After
24 hours of incubation, the percentage of cells in G2/M
phase was high (32 ± 3%) among cells treated with DHA
but not among cells treated with CDHA (17 ± 5%), as com-
pared with cells incubated in medium alone (12 ± 1%).
DHA may have induced cell arrest in the early stage of G0/
G1 phase, leading to accumulation of cells in G2/M phase.
Changes in cell cycle regulators and apoptosis inducers
Cell cycle regulatory proteins, including p53, p21Cip1/Waf1,
and cyclin D1, were examined. Representative Western
Figure 3
Cell cycle analysis of synchronous KPL-1 cells grown in medium alone or treated with docosahexaenoic acid (DHA) or conjugated DHA (CDHA) (50% inhibitor  concentration [IC50] for 72 hours, respectively) for up t  24 hours
(50% inhibitory concentration [IC50] for 72 hours, respectively) for up to 24 hours. G0/G1 arrest is seen after DHA and CDHA treatment. All results 
were calculated from three independent experiments. *P < 0.05, **P < 0.01, versus controls at the same time point.
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blotting results are shown in Fig. 4a, and data from three
independent experiments using individually prepared
lysates are summarized in Fig. 5a. Density of immunoreac-
tive bands in DHA-treated or CDHA-treated samples is
expressed as percentage of the density of corresponding
bands in control samples, which were designated 100%. In
KPL-1 cells, both DHA and CDHA at IC50 for 72 hours
increased levels of p53 and p21Cip1/Waf1, and decreased
levels of cyclin D1 at 3, 6 and 24 hours, as compared with
untreated control cells. Changes in the apoptosis acceler-
ating protein Bax and the apoptosis suppressing protein
Bcl-2 were examined 24, 48 and 72 hours after treatment.
Although the level of Bax was not altered at these time
points, a decrease in Bcl-2 level was observed (Figs 4b and
5b).
Effects of CDHA in vivo
There was no evidence of gross toxicity resulting from the
0.2% or 1.0% CDHA diets. There were no significant dif-
ferences in body weight change among groups (Fig. 6) and
no deaths occurred. However, growth of KPL-1 cells, as
evaluated by tumor volume, was always less in CDHA-fed
mice than in CDHA-unfed controls (Fig. 7). At the end of
Figure 4
Expression of (a) p53, p21Cip1/Waf1 and cyclin D1, and (b) Bax and Bcl-2 in KPL-1 cells grown in medium alone (control) or treated with docosahexaenoic acid (DHA) or conjugated DHA (CDHA)
2 in KPL-1 cells grown in medium alone (control) or treated with 
docosahexaenoic acid (DHA) or conjugated DHA (CDHA).
Figure 5
Quantification of (a) p53, p21Cip1/Waf1 and cyclin D1, and (b) Bax and Bcl-2 protein expression in KPL-1 cells treated with docosahex enoic acid (DHA) r conjugated DHA (CDHA), compared with control (desig-nated 100%)
Bcl-2 protein expression in KPL-1 cells treated with docosahexaenoic 
acid (DHA) or conjugated DHA (CDHA), compared with control (desig-
nated 100%). All results were calculated from three independent sam-
ples. *P < 0.05, versus controls.
Figure 6
Effect of dietary conjugated docosahexaenoic acid (CDHA) on body weight change in female BALB/c at ymic mi e before and after KPL-1 inoculation
weight change in female BALB/c athymic mice before and after KPL-1 
inoculation. Values are expressed as mean ± standard error for 10 
mice.
Figure 7
Growth of KPL-1 cells injected subcutaneously into the area of the right thoracic mammary fat pad of female BALB/c athymic mic  at 6 weeks of age
thoracic mammary fat pad of female BALB/c athymic mice at 6 weeks 
of age. Values are expressed as mean ± standard error for 10 tumors. 
CDHA, conjugated docosahexaenoic acid.
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the study tumor volume was significantly reduced in 1.0%
CDHA-treated mice (855 ± 88 mm3) compared with
CDHA-unfed controls (1314 ± 223 mm3; P < 0.05); the
0.2% CDHA diet (1193 ± 138 mm3) had no significant
effect. Although a 26% reduction in tumor weight was
observed in 1.0% CDHA treated mice compared with
CDHA-unfed controls (1170 ± 158 and 1580 ± 261 mg,
respectively), the difference was not significant; tumor
weight was not reduced in 0.2% CDHA treated mice
(1581 ± 157 mg). Axillary lymph node metastasis was
observed in 60% (6/10) of control mice, 50% (5/10) of
0.2% CDHA-treated mice, and 40% (4/10) of 1.0%
CDHA-treated mice (i.e. metastasis gradually decreased
with increasing amount of ingested CDHA). In each dietary
group metastasis tended to correlate with the size of the
primary tumor (Fig. 8). Further experiments are needed to
determine whether metastasis per se is affected by CDHA.
Discussion
DHA inhibited the growth of KPL-1 human breast cancer
cells in vitro, with an IC50 of 270 µmol/l. In a previous study
serum concentration of DHA in rats was 97.3 µg/ml (297
µmol/l) after 4 weeks of DHA supplementation [26]. Thus,
the present IC50 for DHA may be relevant to tumor progres-
sion in vivo. CDHA inhibited KPL-1 cell growth more effec-
tively than did DHA in vitro. CDHA isomerized by alkaline
treatment exhibited cytotoxity, with an IC50 of 97 µmol/l,
which is 2.8-fold more potent than the parent DHA. The
conjugated fatty acid most widely studied for its anticarci-
nogenic effects is CLA, a conjugated dienoic acid. In addi-
tion, conjugated trienoic fatty acids exhibit cytotoxic effects
in cultured human tumor cell lines [27], and conjugated
tetraenes exert cytotoxicity on human leukemia cells [28]. In
the present study CDHA rich in conjugated pentaene and
hexaene was shown to be cytotoxic against KPL-1 human
breast cancer cells.
Garden balsam seed oil, which contains conjugated
tetraenes, and tung, bitter gourd, pomgranata, catalpa and
pot marigolg seed oil, which contain high amounts of con-
jugated trienes, are cytotoxic to tumor cells of mouse and
human origin [28,29]. These naturally occurring seed oils
each contain one major isomer [30]. In contrast, like CLA
formed by partial bacterial hydrogenation of the parent lino-
leic acid in the rumen of ruminant animals, conjugated fatty
acids prepared by alkaline isomerization contain a mixture
of complex positional (location of double bonds) and
geometric (cis/trans combinations) isomers. Determining
which isomer(s) exhibits potent anticarcinogenic action
requires further study.
DHA-induced reduction of tumor cell growth is generally
attributed to induction of apoptotic cell death [31] and its
effects on cell cycle progression [32]. DHA reduces cyclin
D1, E and A associated kinase activity in HT-29 human
colon cancer cells. Thus, DHA may exert its negative effect
on growth of tumor cells by inhibiting activation and expres-
sion of G1-associated cell cycle regulatory proteins [33]. In
the present study, like its parent DHA, CDHA induced
apoptosis and affected cell cycle regulatory proteins. Cell
cycle analysis exhibited G1 arrest, which involves increases
in p53 and p21Cip1/Waf1 and a decrease in G1 cyclin (cyclin
D1). CDHA induces apoptosis in human colorectal adeno-
carcinoma cells [21]. In the present study apoptosis was
seen in KPL-1 cells; the apoptosis cascade involved
downregulation of Bcl-2, whereas Bax expression was
unchanged. Thus, the growth inhibitory mechanisms of
CDHA involve positive regulation of apoptosis and negative
regulation of cell cycle progression.
In the present study, CDHA suppressed growth of human
breast cancer cells transplanted into athymic mice.
Previous studies indicate that CLA is a powerful anticancer
agent in the rat mammary cancer model, with significant
effects of CLA obtained at dietary doses of 1.0% and less
[34]. Suppression of mammary carcinogenesis in rats can
be achieved with a diet containing less than 1.0% conju-
gated α-linolenic acid (derived from perilla oil) [35]. The
dietary doses at which conjugated fatty acids have tumor-
suppressing effects is strikingly low compared with n-3
PUFAs, which require a dietary dose of 5–10% to achieve
comparable effects [8,19,36]. In the present study the
dose of CDHA (0.2–1.0% in the AIN-76A diet) was deter-
Figure 8
Scattergram showing KPL-1 primary tumor volume and lymph node metastasis for diets containing 0%, 0.2%, or 1.0% conjugated docosa-hex enoic acid (CDHA)
metastasis for diets containing 0%, 0.2%, or 1.0% conjugated docosa-
hexaenoic acid (CDHA).
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mined in accordance with findings of previous studies of
conjugated fatty acid. A dietary dose of 1.0% CDHA sup-
pressed KPL-1 cell growth in athymic mice.
Conclusion
CDHA exhibited an inhibitory effect on KPL-1 human breast
carcinoma cells in culture, and modulated apoptosis
cascades and cell cycle progression. Also, CDHA sup-
pressed KPL-1 cell growth in athymic mice with no side
effects. CDHA, which has relatively low toxicity, has poten-
tial as a dietary chemopreventive/chemotherapeutic agent
against human breast cancer, and possibly in management
of other forms of cancer. Determining which positional and
geometric isomers are responsible for this anticarcinogenic
effect will require further study.
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